Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galera Therapeutics Inc GRTX

Healthcare Biotechnology
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in... see more

Recent & Breaking News (OTCPK:GRTX)

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer

GlobeNewswire October 22, 2020

Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer

GlobeNewswire September 22, 2020

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19

GlobeNewswire September 16, 2020

Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

GlobeNewswire September 14, 2020

Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer

GlobeNewswire September 8, 2020

Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

GlobeNewswire August 10, 2020

Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference

GlobeNewswire July 30, 2020

Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer

GlobeNewswire July 13, 2020

Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin

GlobeNewswire May 29, 2020

Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease

GlobeNewswire May 18, 2020

Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program

GlobeNewswire May 13, 2020

Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates

GlobeNewswire May 12, 2020

Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference

GlobeNewswire May 5, 2020

Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program

GlobeNewswire April 30, 2020

Galera Therapeutics Appoints Linda B. West to Board of Directors

GlobeNewswire April 2, 2020

Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments

GlobeNewswire March 10, 2020

Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis

GlobeNewswire February 27, 2020

Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium

GlobeNewswire February 24, 2020

Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

GlobeNewswire February 19, 2020

Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication

GlobeNewswire January 7, 2020